4.4 Article

Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders

期刊

JOURNAL OF INHERITED METABOLIC DISEASE
卷 41, 期 3, 页码 457-477

出版社

SPRINGER
DOI: 10.1007/s10545-017-0126-3

关键词

Lysosomal storage diseases; Tandem mass spectrometry; Biomarkers

资金

  1. Shire
  2. Sanofi-Genzyme
  3. BioMarin Pharmaceuticals
  4. Amicus Therapeutics
  5. Waters Corp.
  6. Actelion Pharmaceuticals

向作者/读者索取更多资源

Tandem mass spectrometry (MS/MS) is a highly sensitive and specific technique. Thanks to the development of triple quadrupole analyzers, it is becoming more widely used in laboratories working in the field of inborn errors of metabolism. We review here the state of the art of this technique applied to the diagnosis of lysosomal storage disorders (LSDs) and how MS/MS has changed the diagnostic rationale in recent years. This fine technology brings more sensitive, specific, and reliable methods than the previous biochemical ones for the analysis of urinary glycosaminoglycans, oligosarcharides, and sialic acid. In sphingolipidoses, the quantification of urinary sphingolipids (globotriaosylecramide, sulfatides) is possible. The measurement of new plasmatic biomarkers such as oxysterols, bile acids, and lysosphingolipids allows the screening of many sphingolipidoses and related disorders (Niemann-Pick type C), replacing tedious biochemical techniques. Applied to amniotic fluid, a more reliable prenatal diagnosis or screening of LSDs is now available for fetuses presenting with antenatal manifestations. Applied to enzyme measurements, it allows high throughput assays for the screening of large populations, even newborn screening. The advent of this new method can modify the diagnostic rationale behind LSDs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据